
THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt as to any aspect of this circular or as to the action to be taken, you should consult a stockbroker or other registered dealer in securities, a bank manager, solicitor, professional accountant or other professional adviser.

If you have sold or transferred all your shares in Genor Biopharma Holdings Limited, you should at once hand this circular, together with the enclosed form of proxy, to the purchaser or transferee or to the bank, stockbroker or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.

**GENOR BIOPHARMA HOLDINGS LIMITED****嘉和生物藥業(開曼)控股有限公司***(Incorporated in the Cayman Islands with limited liability)***(Stock Code: 6998)****PROPOSED REMOVAL AND APPOINTMENT OF AUDITOR
AND
NOTICE OF EXTRAORDINARY GENERAL MEETING**

The notice convening the extraordinary general meeting of Genor Biopharma Holdings Limited to be held at Room 501-02, Building 6, 690 Bibo Road, Pudong New District, Shanghai, China on Wednesday, 19 February 2025 at 10:00 a.m. is set out in this circular.

Whether or not you are able to attend the extraordinary general meeting, please complete and sign the enclosed form of proxy for use at the extraordinary general meeting in accordance with the instructions printed thereon and return it to the Company's share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong as soon as possible but in any event not less than 48 hours before the time appointed for the extraordinary general meeting (i.e. not later than 10:00 a.m. on Monday, 17 February 2025 (Hong Kong time)) or any adjournment thereof (as the case may be). Completion and return of the form of proxy will not preclude you from attending and voting in person at the extraordinary general meeting if you so wish.

This circular together with the form of proxy are also published on the websites of the Stock Exchange (<http://www.hkexnews.hk>) and the Company (<http://www.genorbio.com>).

4 February 2025

CONTENTS

	<i>Page</i>
Definitions	1
Letter from the Board	3
Appendix I – Letter from PwC	I-1
Notice of Extraordinary General Meeting	11

DEFINITIONS

In this circular, unless the context otherwise requires, the following expressions shall have the following meanings:

“Articles of Association”	the articles of association of the Company as amended from time to time
“Audit Committee”	the audit committee of the Board
“Auditor”	the auditor of the Company
“Board”	the board of Directors
“Company”	Genor Biopharma Holdings Limited, a company incorporated under the laws of the Cayman Islands with limited liability and the Shares of which are listed on the Main Board of the Stock Exchange
“Director(s)”	the director(s) of the Company
“EGM”	the extraordinary general meeting of the Company to be held at Room 501-02, Building 6, 690 Bibo Road, Pudong New District, Shanghai, China on Wednesday, 19 February 2025 at 10:00 a.m., to consider and, if appropriate, to approve the resolutions contained in the notice of the EGM which is set out on pages 11 to 12 of this circular, or any adjournment thereof
“EY”	Ernst & Young, the new Auditor proposed to be appointed at the EGM
“Group”	the Company and its subsidiaries
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“Latest Practicable Date”	28 January 2025, being the latest practicable date prior to the printing of this circular for ascertaining certain information contained in this circular
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange

DEFINITIONS

“New Listing Application”	the deemed new listing application in relation to the proposed merger of a wholly-owned subsidiary of the Company with Edding Group Company Limited pursuant to a merger agreement dated 13 September 2024 to be filed by the Company with the Stock Exchange pursuant to the Listing Rules; for details of the proposed merger, please refer to the announcement of the Company dated 7 October 2024
“PRC”	the People’s Republic of China and for the purpose of this circular, excludes Hong Kong, the Macau Special Administrative Region of the People’s Republic of China and Taiwan
“Proposed Appointment”	the proposed appointment of EY as the new Auditor, subject to the approval of the Shareholders at the EGM
“Proposed Change of Auditor”	collectively, the Proposed Removal and the Proposed Appointment
“Proposed Removal”	the proposed removal of PwC as the Auditor, subject to the approval of the Shareholders at the EGM
“PwC”	PricewaterhouseCoopers, the existing Auditor proposed to be removed at the EGM
“Shareholder(s)”	holder(s) of Share(s)
“Shares”	ordinary share(s) of US\$0.00002 each in the issued capital of the Company
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“US\$”	United States dollars, the lawful currency of the United States

LETTER FROM THE BOARD



GENOR BIOPHARMA HOLDINGS LIMITED

嘉和生物藥業(開曼)控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6998)

Executive Director:

Mr. Weng Chengyi (*Chief Financial Officer*)

Non-executive Directors:

Dr. Lyu Dong

Mr. Yu Tieming

Mr. Liu Yi

Independent Non-executive Directors:

Mr. Fung Edwin

Mr. Chen Wen

Ms. Cui Bai

Registered Office:

Maples Corporate Services Limited

PO Box 309, Uglan House

Grand Cayman

KY1-1104

Cayman Islands

Principal Place of Business and

Head Office in the PRC:

Room 501-02, Building 6

690 Bibo Road

Pudong New District, Shanghai

PRC

Principal Place of Business in

Hong Kong:

Room 1920, 19/F

Lee Garden One, 33 Hysan Avenue

Causeway Bay

Hong Kong

4 February 2025

To the Shareholders

Dear Sir/Madam,

**PROPOSED REMOVAL AND APPOINTMENT OF AUDITOR
AND
NOTICE OF EXTRAORDINARY GENERAL MEETING**

1. INTRODUCTION

Reference is made to the announcement of the Company dated 22 January 2025 in relation to the Proposed Change of Auditor.

LETTER FROM THE BOARD

The purpose of this circular is to provide you with the notice of EGM and to provide you with information regarding the resolutions to be put forward at the EGM. Resolutions to be put forward at the EGM are the Proposed Change of Auditor.

2. PROPOSED REMOVAL

At the last annual general meeting of the Company held on 27 June 2024, PwC was reappointed as the Auditor and to hold office until the conclusion of the next annual general meeting of the Company.

However, during the course of December 2024 and January 2025, the Company, the Audit Committee and PwC had multiple discussions in relation to the information and documentation required for the audit of the annual results for the financial year ended 31 December 2024. Although the Company had used all its reasonable endeavours to satisfy the requests, the Company was concerned that the timeline proposed by the Company for publishing the annual results for the financial year ended 31 December 2024 may not be met.

After considering the facts and circumstances, the management of the Company proposed to the Audit Committee the removal of PwC as auditors. The Audit Committee reviewed the management's proposal and after evaluating all relevant information, the Audit Committee agreed with the management's proposal and recommended that the Board seek shareholder approval for the Proposed Removal. The Board is of the view that the Proposed Removal of PwC, together with the Proposed Appointment of EY, will enable the Company to continue to maintain audit quality and at the same time fulfill the timeline, and thus it is in the interests of the Company and the Shareholders as a whole. The Board therefore proposes to seek the approval of the Shareholders regarding the Proposed Removal. The Proposed Removal is subject to the passing of an ordinary resolution at the EGM pursuant to the Articles of Association.

Matters to be brought to the attention of the Shareholders

On 28 January 2025, the Company and the Audit Committee received a representation letter from PwC (the "**Representation Letter**") in accordance with the Code of Ethics for Professional Accountants Section 300 "Change of Auditors of a Listed Issuer of The Stock Exchange of Hong Kong" setting out, among other things, matters that PwC considered necessary to be brought to the attention to the Shareholders and serving as PwC's written representation pursuant to Rule 13.88 of the Listing Rules. Full text of the Representation Letter is set out in the section headed "Appendix I – Letter from PwC" on pages I-1 to I-3 of this circular.

LETTER FROM THE BOARD

The Board and the Audit Committee would like to emphasise that the reasons for the Proposed Removal have been set out in the section headed “Letter from the Board – 2. Proposed Removal” above.

With regard to the incident relating to the suspected misappropriation of funds by a former employee of the Group as mentioned in the Representation Letter, the Company confirmed that the incident was discovered during the course of preparation of financial statements for the purposes of the New Listing Application. Regarding the incident, the Company confirmed that, upon discussion with PwC and the Audit Committee, an investigation was led by the Audit Committee to investigate the incident with the assistance of an external forensic consultant. Based on the findings of the Audit Committee and the external consultant, the Company reported the incident to the public security bureau in the PRC in January 2025. The Company is currently addressing the internal control deficiencies identified and evaluating the effectiveness of the enhanced internal control system. To the best of the knowledge, information and belief of the Directors after having made all reasonable enquiries, the net amount involved in the incident was approximately RMB9.8 million, and the Board was of the view that the incident did not impact on the Group’s day-to-day business operations and did not expect such incident would cause any material adverse impact to the cashflow and financial condition of the Group. As at the Latest Practicable Date, the Company was still in the process of ascertaining the impact of the incident on the annual report for the financial year ended 31 December 2024, and will make further disclosures in relation to the incident as and when appropriate.

Shareholders and investors of the Company are recommended to read the Representation Letter in conjunction with the above section for a full understanding of the Proposed Removal.

3. PROPOSED APPOINTMENT

After considering (i) the audit proposal of EY; (ii) EY’s experience, industry knowledge and technical competence in providing audit work for companies listed on the Stock Exchange; (iii) EY’s independence from the Group and objectivity; (iv) EY’s resources and capabilities including manpower and time; and (v) the Guidance Notes on Change of Auditors issued by the Accounting and Financial Reporting Council, the Audit Committee has assessed and considered EY to be independent, eligible, capable and suitable to act as the Auditor. The Board, with the recommendation of the Audit Committee, has resolved to propose that the Shareholders approve the appointment of EY as the new Auditor to fill the casual vacancy following the removal of PwC and to hold office until the conclusion of the next annual general meeting of the Company. The Proposed Appointment is subject to the Proposed Removal becoming effective and the passing of the ordinary resolution in respect of the Proposed Appointment at the EGM.

LETTER FROM THE BOARD

4. IMPLICATIONS UNDER THE LISTING RULES AND THE ARTICLES OF ASSOCIATION

According to article 29.2 of the Articles of Association, the removal of an Auditor before the expiration of his period of office shall require the approval of an ordinary resolution of the Shareholders in general meeting.

Under Rule 13.88 of the Listing Rules, (a) the Company must not remove its Auditor before the end of the Auditor's term of office without first obtaining Shareholders' approval at a general meeting; (b) the Company must send a circular proposing the removal of the Auditor to Shareholders with any written representations from the Auditor, not less than 10 business days before the general meeting; and (c) the Company must allow the Auditor to attend the general meeting and make written and/or verbal representations to Shareholders at the general meeting.

In compliance with the Articles of Association and the Listing Rules, each of the Proposed Removal and the Proposed Appointment will be proposed as an ordinary resolution at the EGM.

Accordingly, the Company will despatch a copy of this circular to the Shareholders who request printed copies, containing, among other things, the further information on the Proposed Removal and the Proposed Appointment together with the notice of EGM, and also despatch a copy of the same to PwC to invite them to attend the EGM and make written or verbal representations (if any) to the Shareholders at the EGM.

5. CLOSURE OF REGISTER OF MEMBERS

For determining Shareholders' entitlement to attend and vote at the EGM, the register of members of the Company will be closed from Monday, 17 February 2025 to Wednesday, 19 February 2025, both dates inclusive, during which period no transfer of Shares will be registered. In order to be eligible to attend and vote at the EGM, all transfer of Shares accompanied by the relevant share certificates must be lodged with the Company's share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong, for registration not later than 4:30 p.m. on Friday, 14 February 2025.

6. EGM AND PROXY ARRANGEMENT

The notice of the EGM is set out on pages 11 to 12 of this circular.

Pursuant to the Listing Rules and the Articles of Association, any vote of Shareholders at a general meeting must be taken by poll except where the chairman of the general meeting, in good faith, decides to allow a resolution relating to a procedural or administrative matter to be voted on by a show of hands. An announcement on the poll results will be published by the Company after the EGM in the manner prescribed under the Listing Rules.

LETTER FROM THE BOARD

A form of proxy for use at the EGM is enclosed with this circular and such form of proxy is also published on the websites of the Stock Exchange (<http://www.hkexnews.hk>) and the Company (<http://www.genorbio.com>). To be valid, the form of proxy must be completed and signed in accordance with the instructions printed thereon and deposited, together with the power of attorney or other authority (if any) under which it is signed or a certified copy of that power of attorney or authority at the Company's share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong as soon as possible but in any event not less than 48 hours before the time appointed for the EGM (i.e. not later than 10:00 a.m. on Monday, 17 February 2025 (Hong Kong time)) or any adjournment thereof (as the case may be). Completion and delivery of the form of proxy will not preclude you from attending and voting at the EGM if you so wish.

As at the Latest Practicable Date, to the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, no Shareholder is required to abstain from voting on any resolution to be proposed at the EGM.

7. RESPONSIBILITY STATEMENT

This circular, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief, the information contained in this circular is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this circular misleading.

8. RECOMMENDATION

The Directors consider that the resolutions for the Proposed Change of Auditor to be proposed at the EGM are in the interests of the Company and the Shareholders as a whole. The Directors therefore recommend the Shareholders to vote in favour of all the resolutions to be proposed at the EGM.

Yours faithfully,

For and on behalf of the Board

Genor Biopharma Holdings Limited

Mr. Weng Chengyi

Executive Director and Chief Financial Officer

The letter was issued in English. This Chinese version is for reference only. If there is any discrepancy between the English and the Chinese versions, the English version shall prevail.



羅兵咸永道

The Board of Directors & The Audit Committee
Genor Biopharma Holdings Limited
PO Box 309, Ugland House,
Grand Cayman, KY1-1104
Cayman Islands

28 January 2025

Our Ref: Genor/20250128

Dear Sirs

**ANNOUNCEMENT OF
PROPOSED REMOVAL AND APPOINTMENT OF AUDITOR
– Genor Biopharma Holdings Limited**

We, PricewaterhouseCoopers, are writing to the Board of Directors and the Audit Committee in respect of the Company’s announcement issued on 22 January 2025, proposing a change of auditor by removing us (the “**Announcement**”) in the upcoming Extraordinary General Meeting (the “**EGM**”). We have been reappointed on 27 June 2024 to perform an audit of the consolidated financial statements of the Company and its subsidiaries (together, the “**Group**”) for the year ended 31 December 2024. We were provided with a copy of the draft announcement by the Company on the date of issuance of the Announcement. We provided our preliminary comments on the draft to the Company on the same day. Upon receiving our preliminary comments, the Company did not reach out to us for discussion, and we have also not been provided with the final version of the Announcement for review prior to its publication.

We consider that the Announcement will give the public an incomplete and inaccurate understanding of the matters leading to our termination as the auditors of the Company. As elaborated in our letter issued to the Board of Directors and the Audit Committee dated 28 January 2025 under the Code of Ethics for Professional Accountants Section 300 “Change of

Auditors of a Listed Issuer of The Stock Exchange of Hong Kong”, we set out the following being matters leading to our termination as the auditors of the Company (which also represent those that we consider should be brought to the attention of the Company’s members and creditors).

During the course of our work in connection with the proposed very substantial acquisition of Edding Group Company Limited by the Company, we discovered that there was certain unexplainable discrepancy totalling approximately RMB8.5 million in the balance of two bank accounts as of 30 September 2024 in the confirmations received from the bank and the Company’s books and records, which we reported to management of the Company and the audit committee (the “AC”) in November 2024. We have also recommended the AC to conduct an independent investigation. Upon the Company’s investigation, it was discovered that one former employee (a cashier who resigned in November 2024, the “**Former Employee**”) in the finance department of the Group in the People’s Republic of China (the “**PRC**”) had misappropriated certain funds of the Group deposited with several banks in the PRC. This Former Employee also prepared counterfeit documents including but not limited to bank statements to conceal the misappropriation of funds (the “**Misappropriation**”) during August 2022 to November 2024 (the “**Relevant Period**”). An investigation was led by the AC, to investigate the Misappropriation in December 2024. The Company also engaged an independent investigator to conduct a forensic investigation (the “**Forensic Investigation**”) on the Misappropriation and to assist the special committee in investigating matters arising from the Misappropriation. The Company also reported this Misappropriation to the police in Shanghai on 14 January 2025. The police investigation is still ongoing based on our latest understanding from management.

The Forensic Investigation report was finalised in late December 2024. Based on the Forensic Investigation findings, during the Relevant Period, the net amount misappropriated during the Relevant Period was approximately RMB9.8 million which come from withdrawal of approximately RMB19.6 million from, and netted off by RMB9.76 million deposits by the Former Employee and other external companies to, the relevant bank accounts.

Upon the discovery of the Misappropriation, we worked alongside with the independent investigator to understand and evaluate the sufficiency of the scope and to assess the findings of the Forensic Investigation and implications on relevant internal controls. We further reassessed our planned audit procedures upon receipt of the finalised Forensic Investigation report in late December 2024 and engaged resources to carry out additional audit procedures we considered necessary given the circumstances. We have also performed a preliminary assessment on the findings of the Forensic Investigation for the relevant financial impacts on the consolidated financial statements for the year ended 31 December 2024 (the “**2024 Audit**”) and six months ended 30 June 2024 and relevant prior reporting periods. However, we have yet to finalise the abovementioned work and assessment as at the date of the removal proposal.

The statement in the Announcement that “the Company could not reach a consensus with PwC on the audit timeline for the financial year ended 31 December 2024” is not consistent with our understanding. The timeline for the audit of the Company’s financial statements for the 2024 Audit was proposed by the Company before the discovery of the Misappropriation. On 27 December 2024, we had a meeting with AC to discuss the 2024 Audit. During the meeting with the AC and the Chief Finance Officer, it was still agreed that 28 March 2025 would be the tentative report date. We were once verbally informed by the Chief Financial Officer on 2 January 2025 of the Company that they would like to explore acceleration of the proposed result announcement date. Throughout all the discussion about the audit timeline, we have considered carefully the status of our work and time required to complete the audit procedures we considered necessary. On no occasion have we disagreed with the Company that their proposals in respect of the audit timeline for the 2024 Audit could not be met.

Moreover, as explained in the 6th paragraph above regarding the status of our work, we also consider the statement “The Board further confirmed that, as at the date of this announcement, PwC has not commenced any substantive review or audit work except for preliminary planning work in relation to the consolidated financial statements of the Group for the financial year ended 31 December 2024.” in the Announcement is factually incorrect.

This letter serves as our written representation pursuant to Rule 13.88 of the Listing Rules which needs to be brought to the attention of the Company’s shareholders. We respectfully ask the Company to include our representation above in the circular of the EGM prior to its dispatch.

Yours faithfully

A handwritten signature in cursive script that reads "PricewaterhouseCoopers".

PricewaterhouseCoopers

NOTICE OF EXTRAORDINARY GENERAL MEETING



GENOR BIOPHARMA HOLDINGS LIMITED

嘉和生物藥業(開曼)控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6998)

NOTICE OF EXTRAORDINARY GENERAL MEETING

NOTICE IS HEREBY GIVEN that the extraordinary general meeting (the “**EGM**”) of Genor Biopharma Holdings Limited (the “**Company**”) will be held at Room 501-02, Building 6, 690 Bibo Road, Pudong New District, Shanghai, China on Wednesday, 19 February 2025 at 10:00 a.m. to consider and, if thought fit, pass the following ordinary resolutions:

ORDINARY RESOLUTIONS

1. To consider the removal of PricewaterhouseCoopers as the auditor of the Company pursuant to article 29.2 of the articles of association of the Company with immediate effect after the conclusion of the EGM (the “**Removal**”), and the authorisation of the board of directors of the Company (the “**Board**”) and any director(s) of the Company to exercise such discretion to complete and do all such acts and things, including without limitation, to sign, seal, execute and deliver all such documents and deeds, and to approve any amendment, alteration or modification to any document, as they may consider necessary, desirable or expedient or in the interest of the Company to give effect to the Removal.
2. To consider, conditional upon the passing of the resolution 1 above, (i) the appointment of Ernst & Young as the auditor of the Company with immediate effect and to hold office until the conclusion of the next annual general meeting of the Company (the “**Appointment**”); (ii) the authorisation of the Board, any director(s) of the Company or any other person authorised by the directors of the Company to exercise such discretion to complete and do all such acts and things, including without limitation, to sign, seal, execute and deliver all such documents and deeds, and to approve any amendment, alteration or modification to any document, as they may consider necessary, desirable or expedient or in the interest of the Company to give effect to the Appointment; and (iii) the authorisation of the Board to fix the remuneration of Ernst & Young.

By order of the Board

Genor Biopharma Holdings Limited

Mr. Weng Chengyi

Executive Director and Chief Financial Officer

Hong Kong, 4 February 2025

NOTICE OF EXTRAORDINARY GENERAL MEETING

Notes:

1. All resolutions at the meeting will be taken by poll (except where the chairman decides to allow a resolution relating to a procedural or administrative matter to be voted on by a show of hands) pursuant to the Listing Rules. The results of the poll will be published on the websites of the Stock Exchange and the Company in accordance with the Listing Rules.
2. Any shareholder of the Company entitled to attend and vote at the above meeting is entitled to appoint another person as his proxy to attend and vote instead of him. A shareholder who is the holder of two or more shares may appoint more than one proxy to represent him and vote on his behalf at the above meeting. A proxy need not be a shareholder of the Company. If more than one proxy is appointed, the number of shares in respect of which each such proxy so appointed must be specified in the relevant form of proxy.
3. In order to be valid, the form of proxy together with the power of attorney or other authority, if any, under which it is signed or a certified copy of that power of attorney or authority, must be deposited at the Company's share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong, not less than 48 hours before the time appointed for the above meeting (i.e. not later than 10:00 a.m. on Monday, 17 February 2025 (Hong Kong time)) or any adjournment thereof (as the case may be). Delivery of the form of proxy shall not preclude a shareholder of the Company from attending and voting in person at the meeting and, in such event, the instrument appointing a proxy shall be deemed to be revoked.
4. For determining shareholders' entitlement to attend and vote at the above meeting, the register of members of the Company will be closed from Monday, 17 February 2025 to Wednesday, 19 February 2025, both dates inclusive, during which period no transfer of shares will be registered. In order to be eligible to attend and vote at the meeting, all transfer of Shares accompanied by the relevant share certificates must be lodged with the Company's share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong, for registration not later than 4:30 p.m. on Friday, 14 February 2025.

In the event that the meeting is adjourned to a date later than Wednesday, 19 February 2025 due to bad weather conditions or other reasons, the period of closure of the register of members of the Company for determination of shareholders' entitlement to attend and vote at the above meeting will remain the same as stated above.

5. Further information relating to all the matters set out in the above resolutions are set out in the Circular.

As at the date of this notice, the Board comprises Mr. Weng Chengyi as an executive Director; Dr. Lyu Dong, Mr. Yu Tieming and Mr. Liu Yi as non-executive Directors; and Mr. Fung Edwin, Mr. Chen Wen and Ms. Cui Bai as independent non-executive Directors.

<p>This circular (in both English and Chinese versions) has been posted on the Company's website at http://www.genorbio.com.</p>
--